In prostate cancer, USP33 overexpression prevents the degradation of the phosphatase dual-specificity phosphatase 1 (DUSP1), impairing c-jun N-terminal kinase (JNK) activation and apoptosis, which contributes to docetaxel resistance [40]. The gene discussed is USP33; the disease is prostate carcinoma.